167 related articles for article (PubMed ID: 37201797)
1. Increased CMV disease and "severe" BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression.
Petrossian G; Ortiz J; Ortiz AC; Addonizio K; Hsiao A; James R; Koizumi N; Patel S; Plews R
Transpl Immunol; 2023 Aug; 79():101857. PubMed ID: 37201797
[TBL] [Abstract][Full Text] [Related]
2. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
3. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
Chiodo Ortiz A; Petrossian G; Addonizio K; Hsiao A; Koizumi N; Yu Y; Plews R; Conti D; Ortiz J
Transpl Immunol; 2023 Feb; 76():101774. PubMed ID: 36528248
[TBL] [Abstract][Full Text] [Related]
4. Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high-risk cytomegalovirus serostatus kidney transplant recipients.
Magua W; Johnson AC; Karadkhele GM; Badell IR; Vasanth P; Mehta AK; Easley KA; Newell KA; Rickert JB; Larsen CP
Transpl Infect Dis; 2022 Dec; 24(6):e13983. PubMed ID: 36321801
[TBL] [Abstract][Full Text] [Related]
5. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept.
Karadkhele G; Hogan J; Magua W; Zhang W; Badell IR; Mehta A; Lyon M; Pastan S; Pearson TC; Larsen CP
Am J Transplant; 2021 Jan; 21(1):208-221. PubMed ID: 32519434
[TBL] [Abstract][Full Text] [Related]
6. Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.
Tohme FA; Kalil RS; Thomas CP
Transpl Infect Dis; 2015 Feb; 17(1):66-72. PubMed ID: 25582442
[TBL] [Abstract][Full Text] [Related]
7. Factors and outcome in BK virus nephropathy in a Hispanic kidney transplant population.
Pérez-Torres D; Bertrán-Pasarell J; Santiago-Delpín E; González-Ramos M; Medina-Mangual S; Morales-Otero L; González-Caraballo Z
Transpl Infect Dis; 2010 Feb; 12(1):16-22. PubMed ID: 19804584
[TBL] [Abstract][Full Text] [Related]
8. Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients.
Jorgenson MR; Descourouez JL; Lyu B; Astor BC; Saddler CM; Mandelbrot DA; Parajuli S
Clin Transplant; 2020 Mar; 34(3):e13798. PubMed ID: 31994787
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Risk Factors of BK Viremia and Clinical Impact of BK Virus Surveillance on Outcomes in Kidney Transplant Recipients: A Single-Center Cross-Sectional Study.
Ji J; Feng S; Jiang Y; Wang W; Zhang X
Exp Clin Transplant; 2019 Dec; 17(6):727-731. PubMed ID: 30995893
[TBL] [Abstract][Full Text] [Related]
10. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of polyomavirus BK replication and impact of preemptive immunosuppression reduction in renal-transplant recipients in China: a 5-year single-center analysis.
Huang G; Wang CX; Zhang L; Fei JG; Deng SX; Qiu J; Li J; Chen GD; Fu Q; Chen LZ
Diagn Microbiol Infect Dis; 2015 Jan; 81(1):21-6. PubMed ID: 25445121
[TBL] [Abstract][Full Text] [Related]
12. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
13. Predictive Factors of BK Virus Development in Kidney Transplant Recipients and the Effect of Low-Dose Tacrolimus Plus Everolimus on Clinical Outcomes.
Yilmaz VT; Kisaoglu A; Avanaz A; Dandin O; Ozel D; Mutlu D; Akkaya B; Aydinli B; Kocak H
Exp Clin Transplant; 2023 Sep; 21(9):727-734. PubMed ID: 37885288
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy.
Saad ER; Bresnahan BA; Cohen EP; Lu N; Orentas RJ; Vasudev B; Hariharan S
Transplantation; 2008 Mar; 85(6):850-4. PubMed ID: 18360267
[TBL] [Abstract][Full Text] [Related]
15. Stabilization of renal function after the first year of follow-up in kidney transplant recipients treated for significant BK polyomavirus infection or BK polyomavirus-associated nephropathy.
Simard-Meilleur MC; Bodson-Clermont P; St-Louis G; Pâquet MR; Girardin C; Fortin MC; Cardinal H; Hébert MJ; Lévesque R; Renoult E
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28207975
[TBL] [Abstract][Full Text] [Related]
16. BK polyomavirus infection after renal transplantation: Surveillance in a resource-challenged setting.
Bagchi S; Gopalakrishnan V; Srivastava SK; Upadhayay A; Singh G; Bhowmik D; Mahajan S; Dinda A; Agarwal SK
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28834032
[TBL] [Abstract][Full Text] [Related]
17. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen.
Geddes CC; Gunson R; Mazonakis E; Wan R; Thomson L; Clancy M; Carman WF
Transpl Infect Dis; 2011 Apr; 13(2):109-16. PubMed ID: 21457419
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept.
Chavarot N; Divard G; Scemla A; Amrouche L; Aubert O; Leruez-Ville M; Timsit MO; Tinel C; Zuber J; Legendre C; Anglicheau D; Sberro-Soussan R
Am J Transplant; 2021 Jul; 21(7):2448-2458. PubMed ID: 33283406
[TBL] [Abstract][Full Text] [Related]
19. BK viremia surveillance and outcomes in simultaneous pancreas-kidney transplant recipients.
Westphal SG; Lyden ER; Langewisch ED; Miles CD
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28509373
[TBL] [Abstract][Full Text] [Related]
20. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
